Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome

Metabolism: Clinical and Experimental

Volumn 55, Issue 3, 2006, Pages 345-352

  Glueck, Charles J ^a   Sieve, Luann ^a   Zhu, Binghua ^a   Wang, Ping ^a  

^a JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BIRTH; BODY MASS; CONCEPTION; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; GENETIC POLYMORPHISM; GENOTYPE; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; INSULIN RESISTANCE; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 32544437834     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2005.09.008     Document Type: Article

References (54)

1. D.J. Jakubowicz, M.J. Iuorno, and S. Jakubowicz Effects of metformin on early pregnancy loss in the polycystic ovary syndrome J Clin Endocrinol Metab 87 2002 524 529
2. C.J. Glueck, S.G. Awadalla, and H. Phillips Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage Fertil Steril 74 2000 394 397
3. C.J. Glueck, P. Wang, and R.N. Fontaine Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome Metabolism 48 1999 1589 1595
4. Z.M. van der Spuy, and S.J. Dyer The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome Best Pract Res Clin Obstet Gynaecol 18 2004 755 771
5. C.J. Glueck, P. Streicher, and P. Wang Treatment of polycystic ovary syndrome with insulin-lowering agents Expert Opin Pharmacother 3 2002 1177 1189
6. C.J. Glueck, H. Phillips, and D. Cameron Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study Fertil Steril 75 2001 46 52
7. C.J. Glueck, P. Wang, and N. Goldenberg Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin Clin Appl Thromb Hemost 10 2004 323 334
8. C.J. Glueck, H. Phillips, and D. Cameron The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications Metabolism 49 2000 845 852
9. C.J. Glueck, S. Iyengar, and N. Goldenberg Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome J Lab Clin Med 142 2003 35 45
10. E. Diamanti-Kandarakis, G. Palioniko, and K. Alexandraki The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels Eur J Endocrinol 150 2004 793 798
11. C.J. Glueck, P. Wang, and S. Bornovali Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss Metabolism 52 2003 1627 1632
12. M. Sampson, C. Kong, and A. Patel Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome Clin Endocrinol (Oxf) 45 1996 623 629
13. T. Buchholz, P. Lohse, and N. Rogenhofer Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages Hum Reprod 18 2003 2473 2477
14. A. Dossenbach-Glaninger, M. van Trotsenburg, and M. Dossenbach Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss Clin Chem 49 2003 1081 1086
15. I. Juhan-Vague, C. Roul, and M.C. Alessi Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients-relationship with plasma insulin Thromb Haemost 61 1989 370 373
16. C.J. Glueck, P. Wang, and R. Fontaine Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome Metabolism 48 1999 511 519
17. E.M. Velazquez, S. Mendoza, and T. Hamer Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy Metabolism 43 1994 647 654
18. E.M. Velazquez, S.G. Mendoza, and P. Wang Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome Metabolism 46 1997 454 457
19. J. Maly, H. Mala, and M. Pecka Changes of haemostasis in obese subjects during weight reduction Vnitr Lek 47 2001 203 209
20. A. Aljada, R. Garg, and H. Ghanim Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab 86 2001 3250 3256
21. H. Ghanim, R. Garg, and A. Aljada Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese J Clin Endocrinol Metab 86 2001 1306 1312
22. Y.T. Kruszynska, J.G. Yu, and J.M. Olefsky Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects Diabetes 49 2000 633 639
23. V.A. Fonseca, T. Reynolds, and D. Hemphill Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus J Diabetes Complications 12 1998 181 186
24. D.A. Ehrmann, D.J. Schneider, and B.E. Sobel Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome J Clin Endocrinol Metab 82 1997 2108 2116
25. J.C. Gris, S. Ripart-Neveu, and C. Maugard Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study Thromb Haemost 77 1997 1096 1103
26. J.C. Gris, S. Neveu, and P. Mares Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology J Lab Clin Med 122 1993 606 615
27. C.J. Glueck, S. Bornovali, and J. Pranikoff Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome Diabet Med 21 2004 829 836
28. E. Vanky, K.A. Salvesen, and R. Heimstad Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study Hum Reprod 19 2004 1734 1740
29. D. Prisco, C. Fatini, and B. Battaglini Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients Int J Clin Lab Res 30 2000 179 185
30. D.K. Kim, J.W. Kim, and S. Kim Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1 Arterioscler Thromb Vasc Biol 17 1997 3242 3247
31. S.J. Dawson, B. Wiman, and A. Hamsten The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells J Biol Chem 268 1993 10739 10745
32. N.J. Brown, A. Abbas, and D. Byrne Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women Circulation 105 2002 304 309
33. S. Ye, F.R. Green, and P.Y. Scarabin The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde Thromb Haemost 74 1995 837 841
34. B. Lindahl, T.K. Nilsson, and K. Asplund Intense nonpharmacological intervention in subjects with multiple cardiovascular risk factors: decreased fasting insulin levels but only a minor effect on plasma plasminogen activator inhibitor activity Metabolism 47 1998 384 390
35. M. Cigolini, G. Targher, and J.C. Seidell Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men Atherosclerosis 106 1994 139 147
36. M. Henry, D.A. Tregouet, and M.C. Alessi Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort Arterioscler Thromb Vasc Biol 18 1998 84 91
37. L. Byberg, A. Siegbahn, and L. Berglund Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men Arterioscler Thromb Vasc Biol 18 1998 258 264
38. P. Marques-Vidal, P. Sie, and J.P. Cambou Relationships of plasminogen activator inhibitor activity and lipoprotein(a) with insulin, testosterone, 17 beta-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls J Clin Endocrinol Metab 80 1995 1794 1798
39. L. Mykkanen, T. Ronnemaa, and J. Marniemi Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity Arterioscler Thromb 14 1994 1264 1271
40. A. Asplund-Carlson, A. Hamsten, and B. Wiman Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men Diabetologia 36 1993 817 825
41. P. Vague, I. Juhan-Vague, and M.F. Aillaud Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects Metabolism 35 1986 250 253
42. I. Tarkun, Z. Canturk, and B.C. Arslan The plasminogen activator system in young and lean women with polycystic ovary syndrome Endocr J 51 2004 467 472
43. B.E. Sobel Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox Circulation 99 1999 2496 2498
44. J. Dong, S. Fujii, and H. Li Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-{delta} Arterioscler Thromb Vasc Biol 25 2005 1078 1084
45. Z.Y. Hu, Y.X. Liu, and K. Liu Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta J Anat 194 Pt 2 1999 183 195
46. C.H. Graham Effect of transforming growth factor-beta on the plasminogen activator system in cultured first trimester human cytotrophoblasts Placenta 18 1997 137 143
47. C. Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod 19 2004 41 47
48. V.V. Balasa, R.A. Gruppo, and C.J. Glueck The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults Thromb Haemost 81 1999 739 744
49. C.J. Glueck, R.A. Freiberg, and R.N. Fontaine Hypofibrinolysis, thrombophilia, osteonecrosis Clin Orthop 386 2001 19 33
50. D.R. Matthews, J.P. Hosker, and A.S. Rudenski Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
51. C.J. Glueck, N. Goldenberg, and P. Wang Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy Hum Reprod 19 2004 510 521
52. M. Ieko Antiphospholipid antibodies and thrombosis: the putative mechanisms of hypercoagulable state in patients with anticardiolipin antibody Rinsho Byori 48 2000 293 300
53. E.K. Kruithof, C. Tran-Thang, and A. Gudinchet Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors Blood 69 1987 460 466
54. N. Moniwa Relationship of urokinase type plasminogen activator, plasminogen activator inhibitor type 1 and activated protein C in fibrinolysis of human placenta Pol J Pharmacol 48 1996 215 220